tcsc0024653 Alagebrium chloride

Alagebrium chloride is an advanced glycation end product (AGE) inhibitor.

IC50 & Target: AGE^[1]

In Vitro: Alagebrium chloride is an advanced glycation end product (AGE) inhibitor. Endothelial cell (EC) proliferation is increased for all groups receiving Alagebrium (ALT-711), particularly when seeded on matrix from the AAo of obese (ZO) and diabetic (ZD) rats^[2].

In Vivo: Blood pressure is not affected by treatment with Alagebrium. In diabetic RAGE apoE double-KO mice, treatment with Alagebrium is associated with a modest reduction in renal mass and reduces hyperfiltration compare with nontreated mice. Treatment with Alagebrium in diabetic RAGE apoE double-KO mice is associated with a further reduction in glomerular collagen IV levels, approaching levels observed in control mice^[1]. Body weight, heart rate (HR), and mean blood pressure (BP) are similar in Zucker lean (ZL), obese (ZO), and diabetic (ZD) groups in the absence or presence of Alagebrium (ALT-711). Alagebrium increases blood flow (BF) in ZO rats but reduces distal vascular resistance in ZD rats. A decrease in neointimal hyperplasia (NH) intrastrut thickness as a function of local radius is found in all groups with Alagebrium treatment. A significant increase in TGF-β expression is also found in the AAo of ZL rats treated with Alagebrium^[2].